
INFORMATION ONLY

Panzyga, Octagam and Cutaquig Unavailable for Exceptional Access Cases

Customer Letter # 2023-15

2023-06-21

Dear Colleagues:

As announced in [CL 2022-22](#), the outcome of the request for proposals (RFP) for plasma-derived plasma protein and related products (PPRP) resulted in the removal of Panzyga, Octagam and Cutaquig from the PPRP formulary, effective April 1, 2023.

After discussions with the vendor (all three products are manufactured by the same vendor), it was confirmed that bringing limited inventory of these products into Canada for exceptional access cases will not be feasible. As a result, all patients using these products will need to switch to a different product once current inventory is depleted.

Please continue to consult the immunoglobulin share split spreadsheets shared regularly by your hospital liaison specialist for more details.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospital Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier
Director, Plasma Protein and Related Products Formulary Program